Literature DB >> 19383345

Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines.

Naoki Ueda1, Hidenori Shiraha, Tatsuya Fujikawa, Nobuyuki Takaoka, Yutaka Nakanishi, Mayumi Suzuki, Noriyuki Matsuo, Shigetomi Tanaka, Shin-Ichi Nishina, Masayuki Uemura, Akinobu Takaki, Yasushi Shiratori, Kazuhide Yamamoto.   

Abstract

Using GGCX gene-specific real-time PCR, exon 2 deletion splice variant of vitamin K-dependent gamma-glutamyl carboxylase (GGCX) mRNA was identified in HCC cell lines. Expressions of wild type and exon 2 deletion variant of GGCX were analyzed with relevance to DCP production in HCC cell lines. Hep3B, HepG2, HuH1, HuH7, and PLC/PRF/5 produced DCP, while SK-Hep-1, HLE, HLF, and JHH1 produced no detectable level of DCP. DCP-producing cells expressed exon 2 deletion variant of GGCX mRNA and protein, while DCP-negative cells expressed no detectable level of exon 2 deletion variant of GGCX. These results suggest that exon 2 deletion splice variant of GGCX causes dysfunction of GGCX enzyme activity resulting in DCP production in HCC cell lines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19383345      PMCID: PMC5527806          DOI: 10.1016/j.molonc.2008.06.004

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  56 in total

1.  Global cancer statistics.

Authors:  D M Parkin; P Pisani; J Ferlay
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

2.  Identification of an exon 3 deletion splice variant androgen receptor mRNA in human breast cancer.

Authors:  X Zhu; A A Daffada; C M Chan; M Dowsett
Journal:  Int J Cancer       Date:  1997-08-07       Impact factor: 7.396

3.  Substrate recognition by the vitamin K-dependent gamma-glutamyl carboxylase: identification of a sequence homology between the carboxylase and the carboxylase recognition site in the substrate.

Authors:  P A Price; M K Williamson
Journal:  Protein Sci       Date:  1993-11       Impact factor: 6.725

4.  Serum and tissue PIVKA-II expression reflect the biological malignant potential of small hepatocellular carcinoma.

Authors:  Masaya Tamano; Hitoshi Sugaya; Motoo Oguma; Makoto Iijima; Masashi Yoneda; Toshimitsu Murohisa; Kazuo Kojima; Toru Kuniyoshi; Yuichi Majima; Takashi Hashimoto; Akira Terano
Journal:  Hepatol Res       Date:  2002-04       Impact factor: 4.288

5.  The Wilms tumour suppressor protein WT1 (+KTS isoform) binds alpha-actinin 1 mRNA via its zinc-finger domain.

Authors:  A A Morrison; J P Venables; G Dellaire; M R Ladomery
Journal:  Biochem Cell Biol       Date:  2006-10       Impact factor: 3.626

6.  Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.

Authors:  Eiji Ando; Masatoshi Tanaka; Fumihiko Yamashita; Ryoko Kuromatsu; Shigeru Yutani; Kazuta Fukumori; Shuji Sumie; Yoichi Yano; Koji Okuda; Michio Sata
Journal:  Cancer       Date:  2002-08-01       Impact factor: 6.860

Review 7.  Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review.

Authors:  I C Weitz; H A Liebman
Journal:  Hepatology       Date:  1993-10       Impact factor: 17.425

8.  Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation.

Authors:  Motoyuki Otsuka; Naoya Kato; Run-Xuan Shao; Yujin Hoshida; Hideaki Ijichi; Yukihiro Koike; Hiroyoshi Taniguchi; Masaru Moriyama; Yasushi Shiratori; Takao Kawabe; Masao Omata
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

Review 9.  Splice variants as cancer biomarkers.

Authors:  Brigitta M N Brinkman
Journal:  Clin Biochem       Date:  2004-07       Impact factor: 3.281

10.  Nucleotide sequence of prothrombin gene in abnormal prothrombin-producing hepatocellular carcinoma cell lines.

Authors:  M Tagawa; M Omata; M Ohto
Journal:  Cancer       Date:  1992-02-01       Impact factor: 6.860

View more
  6 in total

1.  Exon 2 skipping eliminates γ-glutamyl carboxylase activity, indicating a partial splicing defect in a patient with vitamin K clotting factor deficiency.

Authors:  Mark A Rishavy; Kevin W Hallgren; Haitao Zhang; Kurt W Runge; Kathleen L Berkner
Journal:  J Thromb Haemost       Date:  2019-06-07       Impact factor: 5.824

Review 2.  Vitamin K and hepatocellular carcinoma: The basic and clinic.

Authors:  Xia Jinghe; Toshihiko Mizuta; Iwata Ozaki
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

3.  Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines.

Authors:  Naoki Ueda; Hidenori Shiraha; Tatsuya Fujikawa; Nobuyuki Takaoka; Yutaka Nakanishi; Mayumi Suzuki; Noriyuki Matsuo; Shigetomi Tanaka; Shin-Ichi Nishina; Masayuki Uemura; Akinobu Takaki; Yasushi Shiratori; Kazuhide Yamamoto
Journal:  Mol Oncol       Date:  2008-06-20       Impact factor: 6.603

4.  Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.

Authors:  Shu-Xiang Cui; Wen-Na Shi; Zhi-Yu Song; Shu-Qing Wang; Xin-Feng Yu; Zu-Hua Gao; Xian-Jun Qu
Journal:  Oncotarget       Date:  2016-06-14

5.  Prognostic values of a novel multi-mRNA signature for predicting relapse of cholangiocarcinoma.

Authors:  Han Guo; Jie Cai; Xuan Wang; Bingrui Wang; Fang Wang; Xiang Li; Xiaoye Qu; Xianming Kong; Yueqiu Gao; Hailong Wu; Xuehua Sun; Qiang Xia; Xiaoni Kong
Journal:  Int J Biol Sci       Date:  2020-01-16       Impact factor: 6.580

6.  Gla-rich protein is a potential new vitamin K target in cancer: evidences for a direct GRP-mineral interaction.

Authors:  Carla S B Viegas; Marjolein Herfs; Marta S Rafael; José L Enriquez; Alexandra Teixeira; Inês M Luís; Cynthia M R van 't Hoofd; Alexandre João; Vera L Maria; Sofia Cavaco; Ana Ferreira; Manuel Serra; Elke Theuwissen; Cees Vermeer; Dina C Simes
Journal:  Biomed Res Int       Date:  2014-05-18       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.